Fuster V., Badimon L., Badimon J., et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med326:242, 1992
3.
Tolleson T., Harrington R.Thrombosis in acute coronary syndrome and coronary intervention, in Lincoff AM, Topol EJ (eds): Platelet Glycoprotein IIb/IIIa Inhibitors. Totowa, NJ, Humana Press, 1999, pp 3-34
4.
Coller B.Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy. Circulation92:2373, 1995
5.
Coller B.Glycoprotein IIb/IIIa antagonists: Development of abciximab and pharmacology of select agents, in Lincoff AM, Topol EJ (eds): Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Totowa, NJ, Humana Press, 1999, pp 67-89
6.
Lefkovits J. , Plow E., Topol E.Platelet glycoprotein IIb/IIIa receptor in cardiovascular medicine. N Engl J Med332:1553, 1995
7.
The EPIC Investigators.Use of A monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med330:956, 1994
8.
Topol E., Ferguson J., Weisman H., et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA278:479, 1997
9.
The EPILOG Investigators.Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med336:1689, 1997
10.
The EPISTENT Investigators.Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet352:87, 1998
11.
Kleiman N.GP IIb/IIIa antagonists. Clinical experience and potential uses in cardiology . Drugs R and D5:361, 1999
12.
The RESTORE Investigators.Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation96:1445, 997
13.
Salame M., King S., Chronos N.Tirofiban in coronary intervention the RESTORE trial, in Lincoff AM, Topol EJ (eds): Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Totowa, NJ, Humana Press , 1999, pp 127-142
14.
TheImpact-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II . Lancet349:1422, 1997
15.
O'Shea, Conor , Tcheng J.Eptifibatide in coronary intervention the IMPACT trials, Lincoff AM, Topol EJ (eds): Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease (Rev. ed., pp. 115-126). Totowa, NJ, Humana Press, 1999, pp 115-126
16.
The PURSUIT Trial Investigators.Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med339:436, 1998
17.
TheCAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet349:1429, 1997
18.
Hamm C., Heeschen C., Goldmann B., et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med340: 1623, 1999
19.
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med338:1498, 1998
20.
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med338:1488, 1998
21.
Brener S., Barr L., Burchenal J., et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction . Circulation98:734, 1998
22.
Antman E., Giugliano R., Gibson C., et al. Abciximab facilitates the rate and extent of thrombolysis Results of the thrombolysis in myocardial infarction (TIMI) 14 trials. Circulation99:2720, 1999
23.
Ohman E., Kleiman N., Gacioch G., et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Circulation95:846, 1997
24.
Lincoff A., Topol E.Overview of the glycoprotein IIb/IIIa inhibitor interventional trials, Lincoff AM, Topol EJ (eds): Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Totowa, NJ. Humana Press , 1999, pp 169-197
25.
ReoPro [package insert]. Indianapolis, IN : Eli Lilly and Company; 1998
26.
Tcheng J., Kereiakes D., Braden G., et al. Safety of abciximab retreatment—final clinical report of the ReoPro re-administration registry (R3). Circulation98:1, 1998
27.
Tam S., Sassoli P., Jordan R., et al. Abciximab (reoPro, chimeric 7E3 fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and αvβ3 integrins. Circulation98:1085, 1998
28.
Neumann F., Zohlnhofer D., Fakhoury L., et al. Effect of Glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin mac-1 in acute myocardial infarction. J Am Coll Cardiol34:1420, 1999
29.
Giugliano R. , Hyatt R.Thrombocytopenia With GP IIb/IIIa Inhibitors: A meta-analysis. J Am Coll Cardiol31:185A, 1998
30.
Mark D.Economics of glycoprotein IIb/IIIa inhibition, in Lincoff AM, Topol EJ (eds): Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Totowa, NJ, Humana Press, 1999, pp 253-266
31.
Heeschen C. , Hamm C., Goldmann B., et al. Cost effectiveness of abciximab in patients with unstable angina according to the troponin T status. Circulation98:I-358, 1998
32.
Weintraub W. , Culler S., Boccuzzi S., et al. Economic impact of GP IIB/IIIA blockade after high risk angioplasty. J Am Coll Cardiol34:1061, 1999
33.
Weintraub W. , Culler S., Kosinski A., et al. Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat angina with aggreastate [tirofiban] and determine cost of therapy with invasive or conservative strategy)-TIMI 18 trial. Am J Cardiol83:317, 1999
34.
Frelinger A. , Hillman R.Novel methods for assessing platelet function . Am Heart J136:S184, 1998
35.
Mascelli M. , Worley S., Veriabo N., et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation96:3860, 1997
36.
Varon D., Lashevski H., Brenner B., et al. Cone and plate (let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von willegrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J135:S 187, 1998
37.
Topol E.Current and emerging anti-thrombotic therapies for acute coronary syndromes . J Invasive Cardiol10:2D, 1998
38.
Kong D., Califf R., Miller D., et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/ IIIa integrin in ischemic heart disease. Circulation98:2829, 1998
